Qu, Changbo <br/><br/>
FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis.  [electronic resource] 

 -  Antiviral research  10 2019 
 - 104588 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-9096 
<br/><br/><label>Standard No.: </label>10.1016/j.antiviral.2019.104588  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--pharmacology<br/>Caspases--metabolism<br/>Cell Line, Tumor<br/>Drug Evaluation, Preclinical<br/>Hepatitis E--drug therapy<br/>Hepatitis E virus--drug effects<br/>Hepatocytes--drug effects<br/>High-Throughput Screening Assays<br/>Host Microbial Interactions--drug effects<br/>Humans<br/>NF-kappa B--metabolism<br/>Receptor-Interacting Protein Serine-Threonine Kinases--metabolism<br/>Signal Transduction<br/>Small Molecule Libraries<br/>Tropanes--pharmacology<br/>United States<br/>United States Food and Drug Administration<br/>Virus Replication--drug effects